This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Advanced therapies in the EU: challenges with HTA and real-world evidence
Published on: Jun 01, 2021
Market access aims to make a health technology not only available and affordable for every patient, but also profitable for the company placing it on the market. Indeed, where a health technology is unprofitable, it does not stay long on the market and becomes unavailable to patients. With advanced therapy medicinal products (ATMPs, or advanced therapies) this is unfortunately common. As of November 2020, five of the 15 ATMPs approved by the European Commission (ChondroCelect®, Glybera®, MACI®, Provenge®, Zalmoxis®) have been withdrawn from the European market, primarily because reimbursement was denied.
ATMPs create a lot of hope for patients and a lot of worries for public budget holders. Due to their characteristics, they are expensive to develop, produce and to follow up after administration. Their expedited development plans and limited evidence packages at marketing authorisation can make value assessment challenging for health technology assessment (HTA) bodies.
This article aims to shed light on the success factors to obtain – in the best timelines – and maintain positive HTA recommendations in Europe. It focuses on some of the larger European economies, namely England, Germany, and France, and refers to Italy’s pay-by-result expertise when dealing with post-launch evidence generation.
Download the full resource now
Fill in the form to download the content